-
公开(公告)号：US12065504B2
公开(公告)日：2024-08-20
申请号：US17488723
申请日：2021-09-29
Applicant: GO Therapeutics, Inc.
Inventor： Thayer White
IPC: C07K16/30 , A61K39/00 , A61K47/68 , A61P35/00 , C07K14/47 , C07K14/54 , C07K14/705 , C07K14/715 , C07K14/725 , C07K16/28 , C07K16/46 , G01N33/574 , G01N33/68
CPC classification number: C07K16/3092 , A61K39/00117 , A61K47/6849 , A61K47/6851 , A61K47/6869 , A61K47/6897 , A61P35/00 , C07K14/4727 , C07K14/5443 , C07K14/7051 , C07K14/70517 , C07K14/70521 , C07K14/70578 , C07K14/7155 , C07K16/2809 , C07K16/468 , G01N33/574 , G01N33/57469 , G01N33/6854 , A61K2039/505 , C07K2317/31 , C07K2317/34 , C07K2317/35 , C07K2317/522 , C07K2317/524 , C07K2317/526 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/622 , C07K2317/76 , C07K2317/92 , C07K2319/30 , G01N2333/4725 , C07K16/3092 , A61K2300/00
Abstract: The present disclosure relates to anti-glyco-MUC1 antibodies and antigen binding fragments thereof that specifically bind to a cancer-specific glycosylation variant of MUC1 and related fusion proteins and antibody-drug conjugates, as well as nucleic acids encoding such biomolecules. The present disclosure further relates to use of the antibodies, antigen-binding fragments, fusion proteins, antibody-drug conjugates and nucleic acids for cancer therapy.
-
公开(公告)号：US20240226207A1
公开(公告)日：2024-07-11
申请号：US18558859
申请日：2022-05-04
Applicant: Janssen Biotech, Inc.
Inventor： David Baillat , Matthew Mulvey
CPC classification number: A61K35/763 , A61K47/6897 , A61P35/00 , C07K16/14 , C07K16/18 , C07K16/28 , C07K16/2803 , C07K16/2833 , C07K16/3069 , C12N15/86 , C07K2317/31 , C07K2317/569 , C07K2317/622 , C12N2710/16622 , C12N2710/16632 , C12N2710/16643 , C12N2710/16671
Abstract: Provided herein are bispecific adaptor proteins and their use for retargeting oncolytic HSV to target cells, such as tumor cells.
-
3.发明授权公开(公告)号：US12005103B2
公开(公告)日：2024-06-11
申请号：US17228001
申请日：2021-04-12
Applicant: University of Maryland, Baltimore
Inventor： Eduardo Davila , Koji Tamada
IPC: A61K39/00 , A61K35/17 , A61K39/395 , A61K47/54 , A61K47/68 , C07K16/28 , C07K16/44 , C12N5/0783
CPC classification number: A61K39/0011 , A61K35/17 , A61K39/39558 , A61K47/555 , A61K47/6855 , A61K47/6859 , A61K47/6863 , A61K47/6897 , C07K16/2863 , C07K16/44 , C12N5/0636 , A61K2039/5156 , A61K2039/572 , A61K2039/585 , C07K2317/622 , C07K2319/00 , C12N2501/515 , C12N2510/00
Abstract: The present invention provides a universal, yet adaptable, anti-tag chimeric antigen receptor (AT-CAR) system which provides T cells with the ability and specificity to recognize and kill target cells, such as tumor cells, that have been marked by tagged antibodies. As an example, αFITC-CAR-expressing T cells have been developed that specifically recognize various human cancer cells when those cells are bound by cancer-reactive FITC-labeled antibodies. The activation of αFITC-CAR-expressing T cells is shown to induce efficient target lysis, T cell proliferation, and cytokine/chemokine production. The system can be used to treating subjects having cancer.
-
公开(公告)号：US20230405144A1
公开(公告)日：2023-12-21
申请号：US18199154
申请日：2023-05-18
Applicant: Senti Biosciences, Inc.
Inventor： Rocky CHEUNG , Russell Morrison GORDLEY , Timothy Kuan-Ta LU , Michelle Elizabeth HUNG , Rebecca Tayler COTTMAN
CPC classification number: A61K47/6897 , A61K47/64 , A61K47/6425 , A61K47/67 , A61K47/6815 , A61K47/6813 , A61K47/6829
Abstract: Provided herein are compositions and methods for inducing cell death in a regulated manner, for example in a safety switch system. Inducible cell death can be triggered by ligand binding to a one or more ligand binding domains. Cell death can include induction of apoptosis.
-
5.发明公开公开(公告)号：US20230165947A1
公开(公告)日：2023-06-01
申请号：US17818526
申请日：2022-08-09
Applicant: Becton, Dickinson and Company
Inventor： Brian P. Dwyer
IPC: A61K39/00 , C07F9/6584 , G01N33/94 , A61K47/68 , A61K47/54 , C07K16/06 , C12N5/16 , G01N33/531
CPC classification number: A61K39/0013 , C07F9/65846 , G01N33/9493 , G01N33/94 , A61K47/6843 , A61K47/555 , A61K47/6897 , C07K16/065 , C12N5/163 , G01N33/531
Abstract: The present application relates to antibodies that bind to small molecules such as cyclophosphamide, ifosfamide, and analogs thereof, and immunological assays for determining the presence and/or quantifying the amount of cyclophosphamide and/or ifosfamide in a sample. By way of example, such immunological assays can be used for environmental testing.
-
Patent Agency Ranking
公开(公告)号：US20230144534A1
公开(公告)日：2023-05-11
申请号：US17948684
申请日：2022-09-20
Applicant: TAGWORKS PHARMACEUTICALS B.V. , SYNCOM B.V.
Inventor： Marc Stefan ROBILLARD , Wolter TEN HOEVE , Freek Johannes Maria HOEBEN , Ronny Mathieu VERSTEEGEN , Hendricus Marie JANSSEN , Arthur Henry Antoon Marie VAN ONZEN , Raffaella ROSSIN
CPC classification number: A61K47/6889 , C07D257/08 , A61K47/555 , A61K47/6897 , C07K16/3046 , A61K47/66 , C07K16/30 , A61K47/60 , A61K47/6817 , A61K47/6415 , C07K2317/626 , A61K2039/505
Abstract: Disclosed is an advancement in provoked chemical cleavage. Thereby the invention provides the use of a diene as a chemically cleavable group attached to a Construct, and the use of a dienophile to provoke the release of the Construct by allowing the diene to react with a dienophile capable of undergoing an inverse electron demand Diels Alder reaction with the diene. The invention includes a kit for releasing a Construct CA bound to a Trigger TR, the kit having a tetrazine and a dienophile, wherein the Trigger is the tetrazine. The invention also includes the use of the formation of a pyridazine by reacting a tetrazine having a Construct CA bound thereto and a dienophile, as a chemical tool for the release, in a chemical, biological or physiological environment, of the Construct.
-
公开(公告)号：US10016412B2
公开(公告)日：2018-07-10
申请号：US15374272
申请日：2016-12-09
Applicant: YALE UNIVERSITY
Inventor： David Spiegel , Kelly Fitzgerald
IPC: A61K31/56 , A61K31/4745 , A61K47/48 , C07D471/04
CPC classification number: A61K31/4745 , A61K31/53 , A61K45/06 , A61K47/60 , A61K47/66 , A61K47/6869 , A61K47/6897 , B82Y5/00 , C07D471/04 , C07K16/44 , C07K2317/732
Abstract: The present invention relates to chimeric chemical compounds which are used to recruit antibodies to cancer cells, in particular, prostate cancer cells or metastasized prostate cancer cells. The compounds according to the present invention comprise an antibody binding terminus (ABT) moiety covalently bonded to a cell binding terminus (CBT) and Toll-like receptor agonist (TLR) through a linker and a multifunctional connector group or molecule.
-
8.发明授权公开(公告)号：US09913921B2
公开(公告)日：2018-03-13
申请号：US14115455
申请日：2012-05-07
Applicant: Marc Stefan Robillard , Johan Lub , Raffaella Rossin , Sandra Martina Van Ben Bosch , Ronny Mathieu Versteegen
Inventor： Marc Stefan Robillard , Johan Lub , Raffaella Rossin , Sandra Martina Van Ben Bosch , Ronny Mathieu Versteegen
IPC: A61K51/10 , A61K51/04 , B82Y5/00 , C07D207/46 , C07D235/02 , C07D245/02 , C07D249/16 , A61K47/68 , A61K49/10
CPC classification number: A61K51/1093 , A61K47/6897 , A61K49/106 , A61K51/041 , A61K51/0495 , A61K51/0497 , B82Y5/00 , C07D207/46 , C07D235/02 , C07D245/02 , C07D249/16
Abstract: Described is a pretargeting method, and related kits, for targeted medical imaging and/or therapeutics, wherein use is made of abiotic reactive chemical groups that exhibit bio-orthogonal reactivity towards each other. The invention involves the use of [4+2] inverse electron demand (retro) Diels-Alder chemistry in providing the coupling between a Pre-targeting Probe and an Effector Probe. To this end one of these probes comprises an electron-deficient tetrazine or other suitable diene, and the other an E-cyclooctene which has a flattened structure as a result of the position of at least two exocyclic bonds.
-
公开(公告)号：US20170088635A1
公开(公告)日：2017-03-30
申请号：US15366629
申请日：2016-12-01
Applicant: IBC Pharmaceuticals, Inc.
Inventor： Chien-Hsing Chang , David M. Goldenberg
IPC: C07K16/46 , C07K16/18 , C07K16/28 , C07K16/30 , A61K39/39 , A61K31/713 , A61K38/46 , A61K39/00 , A61K39/275 , A61K51/10 , C07K16/24
CPC classification number: C07K16/468 , A61K38/465 , A61K39/0011 , A61K39/39 , A61K47/6897 , A61K2039/505 , C07K16/18 , C07K16/243 , C07K16/249 , C07K16/2833 , C07K16/2851 , C07K16/2863 , C07K16/2887 , C07K16/30 , C07K16/3007 , C07K16/3092 , C07K2317/31 , C07K2317/35
Abstract: Disclosed herein are methods and compositions dock and lock (DNL) complexes comprising an AD moiety selected from an AKAP protein and a DDD moiety selected from a protein kinase A regulatory subunit. Also disclosed are fusion proteins comprising an AD moiety or DDD moiety attached to an effector moiety. The DDD moieties form dimers that bind to the AD moiety to form the DNL complexes. The effector moieties may be selected from a wide range of known effector moieties that produce one or more physiological effects, including but not limited to cell death. The DNL complexes may further comprise one or more diagnostic and/or therapeutic agents. The DNL complexes are of use for treating and/or diagnosing a variety of diseases or conditions.
-
公开(公告)号：US20170087148A1
公开(公告)日：2017-03-30
申请号：US15374272
申请日：2016-12-09
Applicant: YALE UNIVERSITY
Inventor： David Spiegel , Kelly Fitzgerald
IPC: A61K31/4745 , C07D471/04
CPC classification number: A61K31/4745 , A61K31/53 , A61K45/06 , A61K47/60 , A61K47/66 , A61K47/6869 , A61K47/6897 , B82Y5/00 , C07D471/04 , C07K16/44 , C07K2317/732
Abstract: The present invention relates to chimeric chemical compounds which are used to recruit antibodies to cancer cells, in particular, prostate cancer cells or metastasized prostate cancer cells. The compounds according to the present invention comprise an antibody binding terminus (ABT) moiety covalently bonded to a cell binding terminus (CBT) and Toll-like receptor agonist (TLR) through a linker and a multifunctional connector group or molecule.
-
-
-
-
-
-
-
-
-
Search Results
287
records
(took 0.06 seconds)
